5-HT7 receptor: Difference between revisions
Appearance
Content deleted Content added
m External link added |
|||
Line 33: | Line 33: | ||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
==External link== |
|||
* {{cite web | url = http://www.iuphar-db.org/GPCR/ReceptorDisplayForward?receptorID=2337 | title = 5-HT<sub>7</sub> | accessdate = | author = | authorlink = | coauthors = | date = | format = | work = IUPHAR Database of Receptors and Ion Channels | publisher = International Union of Basic and Clinical Pharmacology | pages = | language = | archiveurl = | archivedate = | quote = }} |
|||
==Further reading== |
==Further reading== |
Revision as of 11:15, 25 November 2008
Template:PBB 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled), also known as HTR7, is a human gene.[1]
The neurotransmitter, serotonin, is thought to play a role in various cognitive and behavioral functions. The serotonin receptor encoded by this gene belongs to the superfamily of G protein-coupled receptors and the gene is a candidate locus for involvement in autistic disorder and other neuropsychiatric disorders. Three splice variants have been identified which encode proteins that differ in the length of their carboxy terminal ends.[1]
Ligands
Numerous ligands bind to the 5-HT7 receptor:[2][3]
- N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl- 1-piperazinehexanamides[4][5] (can be either agonists or antagonists depending on side chain substitution)
Agonists
- AS-19 - potent agonist, IC50 0.83nM
- LP-12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide)
- LP-44 (4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide)
- 8-OH-DPAT (mixed 5-HT1A / 5-HT7 agonist)[6]
Antagonists
- SB-656,104-A[7]
- 3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]-butyl}-3-ethyl-6-fluoro- 1,3-dihydro-2 H-indol-2-one[8]
- EGIS-12233 - mixed 5-HT6 / 5-HT7 antagonist
Inverse Agonists
- SB-269,970: quasi-full inverse agonist[9][10]
- SB-691,673: full inverse agonist[11]
- SB-258,741: partial inverse agonist[9]
- SB-258,719: partial inverse agonist[11][12] or silent antagonist?[9]
See also
References
- ^ a b "Entrez Gene: HTR7 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)".
- ^ Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007). "5-HT7 receptor ligands: recent developments and potential therapeutic applications". Mini Rev Med Chem. 7 (9): 945–60. PMID 17897083.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Leopoldo M (2004). "Serotonin(7) receptors (5-HT(7)Rs) and their ligands". Curr. Med. Chem. 11 (5): 629–61. PMID 15032609.
- ^ Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (2007). "Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2". J. Med. Chem. 50 (17): 4214–21. doi:10.1021/jm070487n. PMID 17649988.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Leopoldo M, Berardi F, Colabufo NA; et al. (2004). "Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents". J. Med. Chem. 47 (26): 6616–24. doi:10.1021/jm049702f. PMID 15588097.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) - ^ Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A (2004). "8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production". Neuropharmacology. 46 (1): 52–62. doi:10.1016/j.neuropharm.2003.08.007. PMID 14654097.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Forbes IT, Douglas S, Gribble AD; et al. (2002). "SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties". Bioorg. Med. Chem. Lett. 12 (22): 3341–4. PMID 12392747.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Volk B, Barkóczy J, Hegedus E; et al. (2008). "(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists". J. Med. Chem. 51 (8): 2522–32. doi:10.1021/jm070279v. PMID 18361484.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ a b c Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". Eur. J. Pharmacol. 495 (2–3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Lovell PJ, Bromidge SM, Dabbs S; et al. (2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970)". J. Med. Chem. 43 (3): 342–5. PMID 10669560.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) - ^ a b Romero G, Pujol M, Pauwels PJ (2006). "Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists". Naunyn Schmiedebergs Arch. Pharmacol. 374 (1): 31–9. doi:10.1007/s00210-006-0093-y. PMID 16967291.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Forbes IT, Dabbs S, Duckworth DM; et al. (1998). "(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist". J. Med. Chem. 41 (5): 655–7. doi:10.1021/jm970519e. PMID 9513592.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link)
External link
- "5-HT7". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
{{cite web}}
: Cite has empty unknown parameter:|coauthors=
(help)
Further reading
This article incorporates text from the United States National Library of Medicine, which is in the public domain.